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Escherichia coli 0157 infection masquerading as 'rectal 
bleeding': a further problem for infection control 
Clin Microbiol Infect 1998; 4: 667 
Infection with Escherichia coli 0 1 5 7  can result in a range 
of symptoms, from mild diarrhea to severe hemor- 
rhagic colitis [l]. The appearance of stools from 
patients with severe E. coli 0 1 5 7  colitis has been 
described as 'all blood and no stool' [2], which can be 
mistaken for non-infectious rectal bleeding. 
We have recently seen two separate incidents 
where patients were admitted to our hospitals with a 
diagnosis of rectal bleeding and infection was not 
suspected. Subsequent stool cultures yielded E. coli 
0157  and isolation procedures, as per policy, were 
introduced only after the diagnostic delay. Further 
enquiry elicited a history of preceding diarrhea in both 
cases. In one episode, indistinguishable isolates of E. coli 
were subsequently obtained from two further patients 
and three members of the nursing staff on the same 
hospital ward, indicating cross-infection during the 
window period before isolation was instituted. 
We are aware of other serious incidents of hospital 
cross-infection occurring with this organism [3]. As 
E. coli 0157  has a particularly low infectious dose [I], 
nosocomial transmission can occur when infection 
control procedures are suboptimal [4]. This is more 
likely when staffing levels are inadequate, and patients 
are moved around quickly from ward to ward after 
admission, as happened in our second case. 
We suggest that specific enquiry for a preceding 
history of diarrhea should be made in all cases of rectal 
bleeding, as this may be due to E. coli 0157. if such a 
history is forthcoming, infection precautions should be 
taken from the start. 
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lack of efficacy of ozone therapy in HIV infection 
Clin Microbiol Infect 1998; 4: 667-669 
It has been shown that ozone promptly inactivates 
HIV-1 in vitro [l]  and may alter surface markers in 
HIV-I-infected lymphocytes. However, owing either 
to poor methodology [2] or to multiple comple- 
mentary treatments, the usefulness of ozone therapy in 
vivo remains questionable [3]. The advantages and 
disadvantages of ozone therapy in HIV-1 infection have 
been discussed (41, particularly with regard to the 
potential risk of enhancing HIV-1 replication because 
of the release of tumor necrosis factor-a and/or the 
transient oxidative stress. O n  July 1995, we decided to 
investigate whether a well-standardized method of 
ozonated autohemotherapy (OyAHT) [5] could affect 
immunologic and virologic markers of the course of 
HIV-1 infection in drug-naive patients. This decision 
was taken because: first, some patients refused anti- 
retroviral therapy; second, there was a considerable 
interest in using ozone therapy in HIV infection; and 
third, it could not be foreseen that the actual triple 
antiretroviral regimen would be so effective. The study 
population was limited initially to 10 HIV-1- and 
hepatitis C virus-positive adults enrolled in 1995-96, 
who signed an informed consent to be treated by ozone 
therapy. The treatment consisted of collecting 300 g 
of blood from each patient in a Baxter bag for 
autotransfusion (mod. R0530) and exposing it to 
300 mL of 95% 02/5% 0 3  at an 0 3  concentration of 
67 mg/L (20.1 mg 0 3  per treatment). Because of 
a low prothrombin time (PT), citrate-phosphate- 
dextrose-adenine (CPDA) was used as the anti- 
coagulant for blood from patient 3263. Blood samples 
from all of the other patients were treated with heparin 
calcium salt (30 U/g blood) after CPDA had been 
eliminated from the bag. Blood was mixed thoroughly 
with the gas, avoiding foaming for at least 5 min until 
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pO2 reached a plateau at about 400 mmHg and ozone 
had fully reacted with blood. immediate retransfusion 
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was completed in about 20 min. OyAHT was carried 
out twice weekly for at  least 16 sessions. Measurements 
performed at weeks 1 and 8 with respect to the initia- 
tion of OpAHT included standard hematologic para- 
meters, pz-microglobulin level, CD4+ T-lymphocyte 
count, HIV-1 p24 antigenernia, and HIV-1 cellular 
DNA and plasma R N A  load as assessed by competitive 
P C R  and RT-PCR procedures [6].  
Three patients withdrew from the trial before 
conipletion for reasons unrelated to the procedure and 
were excluded from data analysis. Because of a marked 
sense of wellbeing, patients 6713, 2189 and 210 
demanded further treatment and underwent 54 O r  
AHT sessions, receiving an overall ozone dose of 
1080 mg evenly distributed in 16.2 L of blood. No 
patient reported any side effect, and hematologic 
parameters remained stable or improved. A few patients 
noted a decreased incidence of oral candidosis and 
herpes labialis. Table 1 shows the results of the %week 
O r A H T  trial. With the exception of patient 3263, 
there was a significant increase in CD4' cell numbers 
(p=O.001 when patient 3263 is not included). Inter- 
estingly, patient 3263 received blood anticoagulated 
with CPDA because of a PT ranging between 62% and 
69%. Use of heparin, by preserving the physiologic 
Ca2+ level in plasma, enhances immune activation [7]. 
CLW T-lymphocyte counts remained practically stable. 
Plasma HIV-1 KNA and leukocyte HIV-1 DNA levels 
were not significantly affected by the treatment, 
suggesting that ozone does not express a direct virucidal 
effect in vivo. HIV-1 p24 antigenemia was and 
remained negative in all patients. Serum pymicro- 
globulin increased significantly, possibly as a result of 
OrAHT-mediated immunologic enhancement [5]. 
Analysis of the three long-term ozone-treated patients 
at week 24 confirmed sustained CD4 counts and stable 
viral load (not shown). 
While in the lay press there have been many 
undocumented claims that O p A H T  is effective in 
HIV-1 infection, the possibility that a supplemental 
oxidative stress may accelerate disease progression by 
enhancing HIV-1 replication in vivo has not been 
tested before. Although the present study analyzed a 
limited number of patients, repeated measurement of 
relevant virologic markers indicated that ozone therapy 
carried out with an accurate and reliable method 
neither improves nor worsens the dynamics of HIV-1 
replication. Ozone-mediated upregulation of HIV-1 
replication could not have occurred, probably because 
the oxidative stress of Oj-AHT is extremely transient 
and actually enhances the expression of superoxide 
disniutase [8] which is normally suppressed by HIV-1 
Tat protein [9]. 
Table 1 Evaluation of surrogate markers in HIV-1 infection before and after ozone therapy 
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